Our company is a university-launched drug discovery venture committed to bringing smiles to patients suffering from intractable diseases and their families. We achieve this by developing innovative antibody therapeutics for conditions currently lacking effective treatments, leveraging the groundbreaking research results of The University of Osaka.

Historically, drug discovery has primarily focused on developing treatments that target intracellular components associated with diseases. While these have significantly contributed to patient care, many diseases are multifactorial and involve complex interactions with various organs. This often leads to challenges concerning efficacy, safety, and treatment resistance.

Our founder, Professor Taniyama, made a pivotal discovery: the presence of "pathological periostin" within the "stroma"—the microenvironment crucial for the growth of diseased cells and tissues. His foundational research further demonstrated that highly specific antibodies targeting and removing this pathological periostin can be effective in treating various conditions, including breast cancer, diabetic retinopathy, and heart disease.

To advance this research into clinical application, we were selected in June 2024 for the Drug Discovery Venture Ecosystem Enhancement Program by the Japan Agency for Medical Research and Development (AMED). We are currently conducting a physician-initiated clinical trial at The University of Osaka Hospital, evaluating the safety and efficacy of our drug in humans, specifically for HER2-negative breast cancer with treatment resistance, metastasis, and recurrence.

Moving forward, we are dedicated to developing highly effective and safe antibody drugs by continually improving the microenvironment (stroma) of various diseased cells and tissues. We will actively pursue collaborations with diverse companies and integrate new technologies to accelerate our progress, aiming to deliver these new medications to patients as quickly as possible.

Our ultimate goal is to introduce innovative Japanese-developed antibody drugs to the global market, contributing to the well-being and smiles of patients and their families worldwide. We sincerely appreciate your continued support and guidance in our endeavors.

Periotherapia Co., Ltd.
President and CEO, COO
Eiji Tahara,Ph.D.

A Message from Our Founder

We are dedicated to developing novel treatments for intractable disease―conditions for which no cure currently exists.

In October 2017, our venture, spun out of　The University of Osaka, was founded with a clear mission: to stand by patients worldwide suffering from challenging diseases and deliver the much-anticipated therapeutic solutions they urgently need.

My journey began with hands-on experience in a cardiovascular tertiary emergency hospital. Witnessing the critical need for therapies to prevent heart failure following myocardial infarction, I embarked on basic research at Faculty of Medicine, The University of Osaka. For over two decades, I've held firm to the belief that "Where there's a will, there's a way."

What started from humble beginnings, through our unique comprehensive analysis, led to a pivotal discovery: changes in gene splicing variants are a crucial target in chronic inflammation. This breakthrough enabled us to develop our own proprietary drug, for which we have secured an international patent.

Our immediate focus is the clinical application of this novel treatment for triple-negative breast cancer, a disease that currently lacks effective therapeutic options. Looking ahead, we envision expanding its application to a range of other critical areas, including the treatment of highly metastatic malignant tumors, the prevention of post-myocardial infarction heart failure, and interventions for diabetic retinopathy and chronic kidney disease.

Our unwavering commitment is to translate groundbreaking research into tangible clinical benefits. We are determined to develop drugs from Japan that will not merely be confined to laboratories but will truly make a difference in patients' lives.

Driven by this philosophy, we aspire to build a company that earns widespread societal trust and support. We sincerely appreciate your continued understanding and support as we work towards these vital goals.

Periotherapia Co., Ltd.
Director and Founder
Yoshiaki Taniyama